Can semaglutide be useful after menopause?
A study of 106 postmenopausal women treated with semaglutide for overweight or obesity found weight loss in both the hormone-therapy and no-hormone-therapy groups. Women using hormone therapy had greater average weight reduction in this observational cohort. The study does not establish that hormone therapy caused the difference or that it should be started to increase weight loss.[1]
The practical answer is that menopause-related concerns belong in an individual clinical review, alongside the reason for considering weight treatment. They do not create a one-size-fits-all combination prescription. You can ask about the study without assuming its comparison determines your own treatment or that a women-focused service has demonstrated a special advantage.
If several concerns are arriving at once, it helps to name them separately. You may want to discuss weight, how you feel in daily life, eating difficulties, a current prescription or an appointment with another clinician. The point is to give each concern an owner and a follow-up plan, rather than expecting one new medicine or one new platform to explain everything.
What the cohort found—and what it did not test
At twelve months, the study reported average total body weight loss of about 16% among hormone-therapy users versus 12% among nonusers. Participants were not randomly assigned to hormone therapy. Differences in the people receiving treatment, their circumstances and other care can influence an observational result even when researchers adjust for measured factors.[1]
An association has several possible explanations
This is why a larger number in one column is not enough to decide what to prescribe. A comparison can be interesting and worth studying without establishing an action for every reader. Ask whether a claim is describing an association, a trial result or an explanation proposed by the researchers. Those are distinct steps in building evidence.
The study also does not compare telehealth brands, demonstrate a result for every GLP-1 product or establish that a particular hormone formulation is best. It cannot validate a package advertised under the language of midlife wellness. A service needs its own clear explanation of care, and a clinician needs to assess each proposed treatment on its own merits.
For a related care conversation, read the nutrition planning guide and ask who provides individual support.
Separate the questions before comparing services
| The question | A useful next step |
|---|---|
| Weight-treatment goals | Ask how your clinician will assess benefit and tolerability over time. |
| Menopause-related concerns | Ask which clinician should assess them and what information they need. |
| Existing hormone treatment | Tell the prescriber what you currently use and who manages it. |
| Several services or prescribers | Ask how records and treatment decisions will be coordinated. |
This is not an invitation to diagnose the cause of a symptom yourself. It is a way to make sure the next appointment has a clear agenda. Write down what you want help understanding and which professional currently knows about it. If you are unsure who should assess something, that uncertainty is itself a useful question to bring.
A simple example is a person who already has a clinician managing menopause care and is considering an online weight service. Before enrolling, ask how the new service obtains the relevant information and communicates with the existing clinician when needed. Do not assume that sharing an app login or checking a box means two care teams have spoken to each other.
If a service offers both treatment categories, ask whether the same clinician reviews them, whether appointments are separate and whether the fees renew independently. A shared brand can make navigation easier without making every part of the clinical or financial relationship identical. These details affect the routine you will actually live with.
Put the evidence in a longer-term frame
STEP 5, a separate randomized trial in adults without diabetes, studied semaglutide over two years and found that average weight reduction could be maintained during continuing treatment. It was not a trial of adding hormone therapy, and it does not settle a menopause-specific treatment decision.[2]
For a reader, the relevant planning question is what the next review will cover. Ask the clinician how goals are being assessed, how unwanted effects are handled and what should prompt an earlier conversation. Our plateau explainer distinguishes continuing at a stable weight from never having responded, without offering a do-it-yourself medication adjustment.
If the care discussion includes nutrition or everyday strength, our nutrition planning article can help prepare questions. Keep those concerns concrete rather than reducing every change to a single label. “This activity has become harder” or “I cannot manage the meals suggested” gives the care team something specific to assess.
Read a midlife offer with the same care as any other
A page that speaks directly to women in midlife may feel more relevant than a general enrollment page. That can help start a conversation, but it does not replace the information needed to compare a service. Ask about the exact product, complete cost, follow-up arrangements and process for referral or in-person assessment. The tone of the marketing cannot answer those questions.
The Gala Health review looks at a women-focused presentation while keeping plan lengths and coordination questions separate. The Hers review offers another service comparison. Neither provider is endorsed by the observational study discussed here. The study involved a clinical cohort, not a trial of these services.
A useful comparison also asks what happens when your needs extend beyond the platform. Can you obtain records easily? Who explains the handoff? Will the membership continue during a referral or interruption? Our GLP-1 provider guide helps organize those service questions without claiming a universal best choice for menopause.
Leave with a coordinated next step
Before the appointment ends, ask for a short summary of what has been decided and what remains open. Which clinician is responsible for each issue? What information will be shared? When is the next review? If another appointment is needed, who arranges it? A clear answer is useful even when the decision is to gather more information before changing anything.
Use the question builder for preparation and the provider checklist to record the service answers. These tools do not need hormone, symptom or medication details. Keep personal health information with your clinicians rather than putting it into a general planning worksheet.
The evidence should make the conversation more thoughtful, not make you feel that you must add a treatment to match a study group. An observational finding can suggest a research question while leaving the personal decision open. The most useful outcome is an informed discussion that considers your circumstances and gives you a dependable way to return with questions.
Sources
- Hurtado MD et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024. DOI: 10.1097/GME.0000000000002310. Retrospective cohort of 106 postmenopausal women. This is an observational association, not random assignment to hormone therapy. ↩
- STEP 5: two-year semaglutide trial ↩